Research ExplorerPublicationsRelationship of serum beta-synuclein with blood biomarkers a...

Relationship of serum beta-synuclein with blood biomarkers and brain atrophy

Standard

Relationship of serum beta-synuclein with blood biomarkers and brain atrophy. / Oeckl, Patrick; Anderl-Straub, Sarah; Danek, Adrian; Diehl-Schmid, Janine; Fassbender, Klaus; Fliessbach, Klaus; Halbgebauer, Steffen; Huppertz, Hans-Jürgen; Jahn, Holger; Kassubek, Jan; Kornhuber, Johannes; Landwehrmeyer, Bernhard; Lauer, Martin; Prudlo, Johannes; Schneider, Anja; Schroeter, Matthias L; Steinacker, Petra; Volk, Alexander E; Wagner, Matias; Winkelmann, Juliane; Wiltfang, Jens; Ludolph, Albert C; Otto, Markus; FTLD consortium.

In: ALZHEIMERS DEMENT, Vol. 19, No. 4, 04.2023, p. 1358-1371.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Oeckl, P, Anderl-Straub, S, Danek, A, Diehl-Schmid, J, Fassbender, K, Fliessbach, K, Halbgebauer, S, Huppertz, H-J, Jahn, H, Kassubek, J, Kornhuber, J, Landwehrmeyer, B, Lauer, M, Prudlo, J, Schneider, A, Schroeter, ML, Steinacker, P, Volk, AE, Wagner, M, Winkelmann, J, Wiltfang, J, Ludolph, AC, Otto, M & FTLD consortium 2023, 'Relationship of serum beta-synuclein with blood biomarkers and brain atrophy', ALZHEIMERS DEMENT, vol. 19, no. 4, pp. 1358-1371. https://doi.org/10.1002/alz.12790

APA

Oeckl, P., Anderl-Straub, S., Danek, A., Diehl-Schmid, J., Fassbender, K., Fliessbach, K., Halbgebauer, S., Huppertz, H-J., Jahn, H., Kassubek, J., Kornhuber, J., Landwehrmeyer, B., Lauer, M., Prudlo, J., Schneider, A., Schroeter, M. L., Steinacker, P., Volk, A. E., Wagner, M., ... FTLD consortium (2023). Relationship of serum beta-synuclein with blood biomarkers and brain atrophy. ALZHEIMERS DEMENT, 19(4), 1358-1371. https://doi.org/10.1002/alz.12790

Vancouver

Oeckl P, Anderl-Straub S, Danek A, Diehl-Schmid J, Fassbender K, Fliessbach K et al. Relationship of serum beta-synuclein with blood biomarkers and brain atrophy. ALZHEIMERS DEMENT. 2023 Apr;19(4):1358-1371. https://doi.org/10.1002/alz.12790

Bibtex

@article{db9976c377af41b2a46d4d200b6d8eb3,
title = "Relationship of serum beta-synuclein with blood biomarkers and brain atrophy",
abstract = "BACKGROUND: Recent data support beta-synuclein as a blood biomarker to study synaptic degeneration in Alzheimer's disease (AD).METHODS: We provide a detailed comparison of serum beta-synuclein immunoprecipitation - mass spectrometry (IP-MS) with the established blood markers phosphorylated tau 181 (p-tau181) (Simoa) and neurofilament light (NfL) (Ella) in the German FTLD consortium cohort (n = 374) and its relation to brain atrophy (magnetic resonance imaging) and cognitive scores.RESULTS: Serum beta-synuclein was increased in AD but not in frontotemporal lobar degeneration (FTLD) syndromes. Beta-synuclein correlated with atrophy in temporal brain structures and was associated with cognitive impairment. Serum p-tau181 showed the most specific changes in AD but the lowest correlation with structural alterations. NfL was elevated in all diseases and correlated with frontal and temporal brain atrophy.DISCUSSION: Serum beta-synuclein changes differ from those of NfL and p-tau181 and are strongly related to AD, most likely reflecting temporal synaptic degeneration. Beta-synuclein can complement the existing panel of blood markers, thereby providing information on synaptic alterations.HIGHLIGHTS: Blood beta-synuclein is increased in Alzheimer's disease (AD) but not in frontotemporal lobar degeneration (FTLD) syndromes. Blood beta-synuclein correlates with temporal brain atrophy in AD. Blood beta-synuclein correlates with cognitive impairment in AD. The pattern of blood beta-synuclein changes in the investigated diseases is different to phosphorylated tau 181 (p-tau181) and neurofilament light (NfL).",
author = "Patrick Oeckl and Sarah Anderl-Straub and Adrian Danek and Janine Diehl-Schmid and Klaus Fassbender and Klaus Fliessbach and Steffen Halbgebauer and Hans-J{\"u}rgen Huppertz and Holger Jahn and Jan Kassubek and Johannes Kornhuber and Bernhard Landwehrmeyer and Martin Lauer and Johannes Prudlo and Anja Schneider and Schroeter, {Matthias L} and Petra Steinacker and Volk, {Alexander E} and Matias Wagner and Juliane Winkelmann and Jens Wiltfang and Ludolph, {Albert C} and Markus Otto and {FTLD consortium}",
note = "{\textcopyright} 2022 The Authors. Alzheimer's & Dementia published by Wiley Periodicals LLC on behalf of Alzheimer's Association.",
year = "2023",
month = apr,
doi = "10.1002/alz.12790",
language = "English",
volume = "19",
pages = "1358--1371",
journal = "ALZHEIMERS DEMENT",
issn = "1552-5260",
publisher = "Elsevier Inc.",
number = "4",

}

RIS

TY - JOUR

T1 - Relationship of serum beta-synuclein with blood biomarkers and brain atrophy

AU - Oeckl, Patrick

AU - Anderl-Straub, Sarah

AU - Danek, Adrian

AU - Diehl-Schmid, Janine

AU - Fassbender, Klaus

AU - Fliessbach, Klaus

AU - Halbgebauer, Steffen

AU - Huppertz, Hans-Jürgen

AU - Jahn, Holger

AU - Kassubek, Jan

AU - Kornhuber, Johannes

AU - Landwehrmeyer, Bernhard

AU - Lauer, Martin

AU - Prudlo, Johannes

AU - Schneider, Anja

AU - Schroeter, Matthias L

AU - Steinacker, Petra

AU - Volk, Alexander E

AU - Wagner, Matias

AU - Winkelmann, Juliane

AU - Wiltfang, Jens

AU - Ludolph, Albert C

AU - Otto, Markus

AU - FTLD consortium

N1 - © 2022 The Authors. Alzheimer's & Dementia published by Wiley Periodicals LLC on behalf of Alzheimer's Association.

PY - 2023/4

Y1 - 2023/4

N2 - BACKGROUND: Recent data support beta-synuclein as a blood biomarker to study synaptic degeneration in Alzheimer's disease (AD).METHODS: We provide a detailed comparison of serum beta-synuclein immunoprecipitation - mass spectrometry (IP-MS) with the established blood markers phosphorylated tau 181 (p-tau181) (Simoa) and neurofilament light (NfL) (Ella) in the German FTLD consortium cohort (n = 374) and its relation to brain atrophy (magnetic resonance imaging) and cognitive scores.RESULTS: Serum beta-synuclein was increased in AD but not in frontotemporal lobar degeneration (FTLD) syndromes. Beta-synuclein correlated with atrophy in temporal brain structures and was associated with cognitive impairment. Serum p-tau181 showed the most specific changes in AD but the lowest correlation with structural alterations. NfL was elevated in all diseases and correlated with frontal and temporal brain atrophy.DISCUSSION: Serum beta-synuclein changes differ from those of NfL and p-tau181 and are strongly related to AD, most likely reflecting temporal synaptic degeneration. Beta-synuclein can complement the existing panel of blood markers, thereby providing information on synaptic alterations.HIGHLIGHTS: Blood beta-synuclein is increased in Alzheimer's disease (AD) but not in frontotemporal lobar degeneration (FTLD) syndromes. Blood beta-synuclein correlates with temporal brain atrophy in AD. Blood beta-synuclein correlates with cognitive impairment in AD. The pattern of blood beta-synuclein changes in the investigated diseases is different to phosphorylated tau 181 (p-tau181) and neurofilament light (NfL).

AB - BACKGROUND: Recent data support beta-synuclein as a blood biomarker to study synaptic degeneration in Alzheimer's disease (AD).METHODS: We provide a detailed comparison of serum beta-synuclein immunoprecipitation - mass spectrometry (IP-MS) with the established blood markers phosphorylated tau 181 (p-tau181) (Simoa) and neurofilament light (NfL) (Ella) in the German FTLD consortium cohort (n = 374) and its relation to brain atrophy (magnetic resonance imaging) and cognitive scores.RESULTS: Serum beta-synuclein was increased in AD but not in frontotemporal lobar degeneration (FTLD) syndromes. Beta-synuclein correlated with atrophy in temporal brain structures and was associated with cognitive impairment. Serum p-tau181 showed the most specific changes in AD but the lowest correlation with structural alterations. NfL was elevated in all diseases and correlated with frontal and temporal brain atrophy.DISCUSSION: Serum beta-synuclein changes differ from those of NfL and p-tau181 and are strongly related to AD, most likely reflecting temporal synaptic degeneration. Beta-synuclein can complement the existing panel of blood markers, thereby providing information on synaptic alterations.HIGHLIGHTS: Blood beta-synuclein is increased in Alzheimer's disease (AD) but not in frontotemporal lobar degeneration (FTLD) syndromes. Blood beta-synuclein correlates with temporal brain atrophy in AD. Blood beta-synuclein correlates with cognitive impairment in AD. The pattern of blood beta-synuclein changes in the investigated diseases is different to phosphorylated tau 181 (p-tau181) and neurofilament light (NfL).

U2 - 10.1002/alz.12790

DO - 10.1002/alz.12790

M3 - SCORING: Journal article

C2 - 36129098

VL - 19

SP - 1358

EP - 1371

JO - ALZHEIMERS DEMENT

JF - ALZHEIMERS DEMENT

SN - 1552-5260

IS - 4

ER -